Perfect Score: TrialHub Achieves 100% Data Accuracy on Reimbursement Status, Outperforming Competitor by 20%
The Challenge
A top 10 Pharma company was planning a clinical trial in a rare disease indication. To select the right countries, they needed to validate the reimbursement status of a monoclonal antibody already part of patients’ treatment options.
But reimbursement status of the drug varied wildly across countries, and getting it wrong could derail the entire trial.
Their team turned to two data platforms: a legacy provider they were already using, and TrialHub. The goal was simple: find out which solution could provide reliable reimbursement status across the 40+ countries the Pharma was considering.
The Real-World Test
The legacy provider relied solely on Health Technology Assessment (HTA) recommendations, some of which were outdated or didn’t reflect the latest reimbursement decisions.
TrialHub, on the other hand, sources real-time data from National Competent Authorities (NCAs), which provide the final reimbursement status and reimbursement applications. TrialHub complements NCA data with thousands of up-to-date HTAs, medical guidelines and millions of peer-reviewed publications to provide the full context of the treatment access per country.
As a result, across all 40+ countries, TrialHub delivered 100% accuracy. In contrast, the legacy provider demonstrated a 20% error rate, failing to catch recent changes in 8 countries that would directly impact country selection and recruitment.
That difference meant the sponsor could avoid launching a trial in countries where SoC would either render patients ineligible or impact their motivation to participate in a trial.
The Impact
Thanks to TrialHub, the team avoided a potential protocol amendment.
Given that 45% of protocol amendments are reportedly due to “flaws in trial design, inconsistencies in the protocol, unfeasible eligibility criteria and recruitment challenges” (1), getting reimbursement status wrong could’ve cost the Pharma over $535,000.
With TrialHub, they also saved weeks of manual verification work and reallocated internal resources to other high-priority projects.
This isn’t an isolated case. TrialHub has consistently outperformed legacy data providers when it comes to accurate, country-level reimbursement and SoC insights that directly affect trial feasibility.
If you’re relying on static (or worse – proxy) data to guide your country strategy, you could be in for a very costly delay.
Want to know how your current data provider compares? Let’s run a test.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811046/
